Perrie Y, Barralet J E, McNeil S, Vangala A
Drug Delivery Research Group, Aston Pharmacy School, Aston University, Aston Triangle, Birmingham B4 7ET, UK.
Int J Pharm. 2004 Oct 13;284(1-2):31-41. doi: 10.1016/j.ijpharm.2004.07.012.
Compared to naked DNA immunisation, entrapment of plasmid-based DNA vaccines into liposomes by the dehydration-rehydration method has shown to enhance both humoural and cell-mediated immune responses to encoded antigens administered by a variety of routes. In this paper we have compared the potency of lipid-based and non-ionic surfactant based vesicle carrier systems for DNA vaccines after subcutaneous immunisation. Plasmid pI.18Sfi/NP containing the nucleoprotein (NP) gene of A/Sichuan/2/87 (H3N2) influenza virus in the pI.18 expression vector was incorporated by the dehydration-rehydration method into various vesicle formulations. The DRV method, entailing mixing of small unilamellar vesicles (SUV) with DNA, followed by dehydration and rehydration, yielded high DNA vaccine incorporation values (85-97% of the DNA used) in all formulations. Studies on vesicle size revealed lipid-based systems formed cationic submicron size vesicles whilst constructs containing a non-ionic surfactant had significantly large z-average diameters (>1500 nm). Subcutaneous vesicle-mediated DNA immunisation employing two DRV(DNA) formulations as well as naked DNA revealed that humoural responses (immunoglobulin total IgG, and subclasses IgG1 and 1gG2a) engendered by the plasmid encoded nucleoprotein were substantially higher after dosing twice, 28 days apart with 10 microg DRV-entrapped DNA compared to naked DNA. Comparison between the lipid and non-ionic based vesicle formulations revealed no significant difference in stimulated antibody production. These results suggest that, not only can DNA be effectively entrapped within a range of lipid and non-ionic based vesicle formulations using the DRV method but that such DRV vesicles containing DNA may be a useful system for subcutaneous delivery of DNA vaccines.
与裸DNA免疫相比,通过脱水-复水法将基于质粒的DNA疫苗包裹于脂质体中,已显示出能增强经多种途径给药的编码抗原的体液免疫和细胞介导免疫反应。在本文中,我们比较了皮下免疫后基于脂质和基于非离子表面活性剂的囊泡载体系统对DNA疫苗的效力。将含有A/四川/2/87(H3N2)流感病毒核蛋白(NP)基因的质粒pI.18Sfi/NP,通过脱水-复水法掺入各种囊泡制剂中。DRV法,即将小单层囊泡(SUV)与DNA混合,随后进行脱水和复水,在所有制剂中均产生了较高的DNA疫苗掺入值(所用DNA的85-97%)。对囊泡大小的研究表明,基于脂质的系统形成阳离子亚微米大小的囊泡,而含有非离子表面活性剂的构建体具有显著更大的z平均直径(>1500 nm)。采用两种DRV(DNA)制剂以及裸DNA进行皮下囊泡介导的DNA免疫,结果显示,与裸DNA相比,用10μg DRV包裹的DNA,每隔28天给药两次后,由质粒编码的核蛋白产生的体液免疫反应(免疫球蛋白总IgG以及亚类IgG1和IgG2a)显著更高。脂质和基于非离子的囊泡制剂之间的比较显示,刺激产生的抗体没有显著差异。这些结果表明,不仅可以使用DRV法将DNA有效地包裹在一系列基于脂质和基于非离子的囊泡制剂中,而且这种含有DNA的DRV囊泡可能是皮下递送DNA疫苗的有用系统。